Last update: Dec. 24, 2018
Minimal risk for breastfeeding and infant.
An iron and aluminum chelator that increases the elimination of both metals from the body.
Used over short periods to treat acute poisoning from these metals and, over longer periods, to treat chronic iron overload, hemochromatosis, hemosiderosis from repeated transfusions due to thalassemia major or other chronic anemias.
Administered subcutaneously, intramuscularly and intravenously.
At least three cases have been reported of infants of mothers suffering from thalassemia major who were treated with deferoxamine and breast-fed without any problems for the infant or in the iron metabolism of the milk (Pafumi 2000, Surbek 1998).
Its low percentage of protein binding makes its excretion in milk possible, but its practically zero oral bioavailability prevents its transfer to the infant’s plasma via ingested breast milk, except in premature babies and the immediate neonatal period in which there may be increased intestinal permeability.
According to expert authors, the possible presence of deferoxamine in breast milk is unlikely to have harmful effects in the infant (Briggs 2017, Pafumi 2000, Jensen 1995) so there is no reason to stop breastfeeding during treatment.
It may be advisable to control the infant’s serum iron levels.
We do not have alternatives for デフェロキサミンメシル酸塩 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM